<DOC>
	<DOCNO>NCT01766583</DOCNO>
	<brief_summary>This open label , 3 + 3 dose escalation study , determine MTD , safety , efficacy PK profile subject relapsed/refractory B-cell malignancy use CC-292 lenalidomide combination therapy . Subjects follow disease progression collection second primary malignancy ( SPM ) event . This dose escalation follow exploratory expansion phase 3 cohort 12 patient .</brief_summary>
	<brief_title>A Phase IB Study Of The BTKi CC-292 Combined With Lenalidomide In Adults Patients With Relapsed/Refractory B-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Histology : 1 . Patients type Bcell Lymphoma except CLL , SLL Waldenström disease eligible dose escalation phase 2 . During expansion phase , patient DLBCL cohort A , mantle cell lymphoma cohort B type Bcell lymphoma except CLL , SLL Waldenström disease cohort C. Other criterion : Signed inform consent Patients relapse refractory NHL ≥1 prior Rituximabcontaining regimen type therapy high priority Aged 18 year . ECOG performance status 02 . Measurable disease define least one single node tumor lesion &gt; 1.5 cm . Life expectancy ≥ 90 day ( 3 month ) . Patients must eligible willing undergo excisional biopsy tumor site lymph node minimum 1 cm baseline 21 day treatment Females childbearing potential ( FCBP ) † must two negative serum urine pregnancy test sensitivity least 25 mIU/mL start lenalidomide first test must perform within 1014 day start lenalidomide treatment second test must perform within 24 hour start lenalidomide FCBP must either commit continue abstinence heterosexual intercourse begin two method birth control , least 4 week start take lenalidomide . FCBP must also agree monthly pregnancy test must counsel minimum every 4 week pregnancy precaution risk fetal exposure . Men must agree father child agree use condom partner child bear potential . Men must also counsel minimum every 4 week pregnancy precaution risk fetal exposure . Previous treatment lenalidomide BTK inhibitor . Central nervous system meningeal involvement . Contraindication drug contain regimen Concomitant use medicine know cause QT prolongation torsades de pointes HIV disease , active hepatitis B C. Any serious active disease comorbid medical condition ( accord investigator 's decision ) ; Any follow laboratory abnormality : Absolute neutrophil count ( ANC ) &lt; 1,500 cells/mm3 ( 1.5 x 109/L ) . Platelet count &lt; 80,000/mm3 ( 80 x 109/L ) Serum SGOT/AST SGPT/ALT &gt; 3.0 x upper limit normal ( ULN ) . Serum total bilirubin &gt; 1.5 ULN except case hemolytic anemia Gilbert 's syndrome . Calculated creatinine clearance ( CockcroftGault formula MDRD ) &lt; 50 mL /min Prior history malignancy lymphoma ( except basal cell squamous cell carcinoma skin carcinoma situ cervix breast Incidental histological finding prostate cancer [ TNM stage T1a T1b ] ) unless subject free disease ≥ 5 year Any serious medical condition , laboratory abnormality , psychiatric illnessthat would prevent subject signing informed consent form . Pregnant lactating female . Prior ≥ Grade 3 allergic reaction/hypersensitivity thalidomide and/or pomalidomide . Prior ≥ Grade 3 rash desquamating ( blister ) rash take thalidomide and/or pomalidomide . Subjects ≥ Grade 2 neuropathy . Use standard experimental anticancer drug therapy within 28 day initiation ( Day 1 ) study drug therapy . Chronic use proton pump inhibitor , H2 antagonists antacid use last 7 day prior first CC292 dose . Patients chronic gastroesophageal reflux disease , dyspepsia , peptic ulcer disease , carefully evaluate suitability treatment prior enrollment study . These medication avoid throughout study . Patients take corticosteroid 4 week prior inclusion , unless administer dose equivalent ≤ 10 mg/day prednisone ( 4 week ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Open label , 3 + 3 dose escalation study follow expansion phase .</keyword>
</DOC>